Specifically, Li et al. and Xi et al. predicted the MGMT promoter methylation status in glioblastoma [13, 14] and Wei et al. investigated the imaging features of WHO grade II-IV astrocytoma [15] using radiomics, suggesting the efficacy of using radiomics to predict the MGMT promoter methylation status. Here, MGMT is linked to astrocytoma (excluding glioblastoma).